Valganciclovir

Restricted
C. diff Risk

None

Oral Bioavailability

NA

Dosing

Treatment/induction dose: 900 mg PO q12hProphylaxis/maintenance dose: 900 mg PO q24h

60+ mL/min40 - 59 mL/min25 - 39 mL/min10 - 24 mL/min0 - 10 mL/min900 mg PO q12h450 mg PO q12h450 mg PO q24h450 mg PO q48h200 mg PO 3 times weekly

60+ mL/min40 - 59 mL/min25 - 39 mL/min10 - 24 mL/min0 - 10 mL/min900 mg PO q24h450 mg PO q24h450 mg PO q48h450 mg PO twice weekly100 mg PO 3 times weekly

Treatment/induction dose:
200 mg PO 3 times weekly - give after dialysis on dialysis days

Prophylaxis/maintenance dose:
100 mg 3 times weekly - give after dialysis on dialysis days

General Information

Adverse Effects

-May cause blood dyscrasias: granulocytopenia, anemia, thrombocytopenia, and aplastic anemia.
-Acute kidney injury

Common Usage

CMV treatment and prophylaxis

Drug Monitoring

CBC-differential and renal function periodically.